The prevalence of neurological conditions is set to rise alongside the ageing population. When developing therapeutics for these conditions we need physiologically relevant systems amenable to assay development. However this is particularly challenging as neuronal cells are non-proliferative and difficult to handle.
This poster describes how Charnwood Discovery has successfully developed a suite of assays to screen compounds against neuronal cells differentiated in-house from iPSC-derived neural stem cells.
